Desoxycortone
From DrugPedia: A Wikipedia for Drug discovery
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | Desoxycortone | + | Desoxycortone(Deoxycorticosterone) |
Pubchem(6166) | Pubchem(6166) | ||
| Line 5: | Line 5: | ||
21-Hydroxypregn-4-ene-3,20-dione. Desoxycorticosterone acetate (DOCA) is used as replacement therapy in ADDISON DISEASE. | 21-Hydroxypregn-4-ene-3,20-dione. Desoxycorticosterone acetate (DOCA) is used as replacement therapy in ADDISON DISEASE. | ||
| - | Pathway(C03205,D07792) | + | '''KEGG Pathway'''(C03205,D07792) |
| - | C21-Steroid hormone metabolism | + | *C21-Steroid hormone metabolism |
| - | Activity Adrenal cortex hormone, mineralocorticoid | + | '''Activity''' Adrenal cortex hormone, mineralocorticoid |
| + | |||
{| border="1;width:100%; height:200px;style=text-align:center" | {| border="1;width:100%; height:200px;style=text-align:center" | ||
|+'''List of PDB files having estriol as a Ligand:''' | |+'''List of PDB files having estriol as a Ligand:''' | ||
| Line 74: | Line 75: | ||
|- | |- | ||
|} | |} | ||
| - | Organism | + | {| border="1;width:100%; height:200px;style=text-align:center" |
| + | |+'''Toxicity:''' | ||
| + | |- | ||
| + | ! style="background:brown; color:white" |Organism | ||
| + | ! style="background:brown; color:white" |Test Type | ||
| + | ! style="background:brown; color:white" |Route | ||
| + | ! style="background:brown; color:white" |Reported Dose (Normalized Dose) | ||
| + | ! style="background:brown; color:white" |Effect | ||
| + | ! style="background:brown; color:white" |Source | ||
| + | |- | ||
|mouse | |mouse | ||
|LD50 | |LD50 | ||
Revision as of 06:02, 31 October 2008
Desoxycortone(Deoxycorticosterone)
Pubchem(6166)
21-Hydroxypregn-4-ene-3,20-dione. Desoxycorticosterone acetate (DOCA) is used as replacement therapy in ADDISON DISEASE.
KEGG Pathway(C03205,D07792)
- C21-Steroid hormone metabolism
Activity Adrenal cortex hormone, mineralocorticoid
| MMDB ID | PDB ID | Reference |
|---|---|---|
| 33237 | 1Y9R | Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin MECrystal structure of a mutant mineralocorticoid receptor responsible for hypertensionNat. Struct. Mol. Biol. v12, p.554-555 |
| 34430 | 2AA7 | Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, Williams SPA ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptorJ. Biol. Chem. v280, p.31283-31293 |
| 59380 | 2Q3Y | Ortlund EA, Bridgham JT, Redinbo MR, Thornton JWCrystal structure of an ancient protein: evolution by conformational epistasisScience v317, p.1544-1548 |
| Physical Property | Value | Units | Temp (deg C) | Source |
|---|---|---|---|---|
| Melting Point | 141.5 | deg C | EXP | |
| log P (octanol-water) | 2.88 | (none) | EXP | |
| Water Solubility | 59.5 | mg/L | 37 | EXP |
| Vapor Pressure | 2.85E-10 | mm Hg | 25 | EST |
| Henry's Law Constant | 1.01E-08 | atm-m3/mole | 25 | EST |
| Atmospheric OH Rate Constant | 1.07E-10 | cm3/molecule-sec | 25 | EST |
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | unreported | 1gm/kg (1000mg/kg) | Journal of Medicinal Chemistry. Vol. 7, Pg. 673, 1964. |
